How much revenue does Sun Pharma Advanced Research make?

Sun Pharma Advanced Research reported 18.79 billion INR in revenue for fiscal year 2026, up 2518.5% from 717.66 million INR in fiscal year 2025.

Where does Sun Pharma Advanced Research make most of its revenue?

India: 98% of revenue by region in fiscal year 2025, followed by Outside India (2%).

What companies are similar to Sun Pharma Advanced Research?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Strides Pharma Science Limited (STAR.NS), Sanofi Cons Healthc IND L (SANOFICONR.BO), Sanofi India Limited (SANOFI.NS), FDC Limited (FDC.NS).

Sun Pharma Advanced Research Company Limited (SPARC.NS) Stock

About Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for tr...

At a glance

Sun Pharma Advanced Research reported revenue of 18.79 billion INR for fiscal year 2026, up 2518.5% from fiscal year 2025, and net income of 15.53 billion INR. India was its largest region in fiscal year 2025, with 98% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2026.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.